A Phase 1/2 interventional study of ARO-DIMERPA and Placebo in Hyperlipidemia; Mixed, sponsored by Arrowhead Pharmaceuticals. Recruiting at 19 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Arrowhead Pharmaceuticals · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Hyperlipoproteinemia Type II with a site in Australia — 5 open to participants now, 5 under way, 1 of them phase 3. Hyperlipoproteinemia Type II · Australia.
Among the 13 studies in Hyperlipoproteinemia Type II with a site in Australia, this one is the 9th largest by planned enrollment, is one of 2 that started in 2025, is one of 3 in phase 1/2, and was the 12th registered.
249 studies on the registry are indexed under Hyperlipoproteinemia Type II; 56 are open to participants now.
Browse Hyperlipoproteinemia Type II studies →5 of the 13 studies in Hyperlipoproteinemia Type II with a site in Australia are open now. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in Australia, United States, Belgium and 17 more countries
Ages 6–17
Verve Therapeutics, Inc. · Sites in Australia, United States, Canada and 3 more countries
Ages 18–70
Verve Therapeutics, Inc. · Sites in Australia, United States, Canada and 3 more countries
Ages 18–70
Editas Medicine, Inc. · Sites in Australia
Ages 18–65
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 36 Hyperlipoproteinemia Type II studies recruiting now, 17 (47%) set no upper age limit and 15 (42%) stop at 75 or younger; 17 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 5 · Phase 3 6
First in 2005; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 78 is below the median of 134 across 178 interventional studies indexed under Hyperlipoproteinemia Type II.
Median enrollment 93 across the 13 interventional studies. Of the 7 that completed or were terminated, 5 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 13 have an industry lead sponsor. The 8 most frequent:
Arrowhead Pharmaceuticals is the lead sponsor of 50 studies on the registry; 9 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 12 (50%) have results posted.
Arrowhead Pharmaceuticals has 3 studies filed under Hyperlipoproteinemia Type II — fewer than ten, so there is no comparison to draw.
1 of the studies in Hyperlipoproteinemia Type II with a site in Australia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07223658Arrowhead PharmaceuticalsStudy of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia | 2027-07 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies in Hyperlipoproteinemia Type II with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD), and effects on low-density lipoprotein cholesterol (LDL-C) and triglycerides (TGs) of single-dose ARO-DIMERPA and multiple doses of ARO-DIMERPA in adult participants with mixed hyperlipidemia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Note: Additional inclusion/exclusion criteria may apply per protocol.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ARO-DIMERPA in single or multiple ascending doses
Drug: ARO-DIMERPA
Placebo (normal saline, 0.9%) in single or multiple matching doses
Drug: Placebo
Subcutaneous (SC) injection
Calculated volume to match active treatment by SC injection
Number of Participants with Treatment-Emergent Adverse Events (TEAEs)
Time frame: Up to Week 36
Percent Change from Baseline in Fasting LDL-C
Time frame: Baseline to Week 36
Percent Change from Baseline in Fasting TGs
Time frame: Baseline to Week 36
Percent Change from Baseline in Serum apoC-III
Time frame: Baseline to Week 36
Percent Change from Baseline in Serum PCSK9
Time frame: Baseline to Week 36
PK of ARO-DIMERPA: Maximum Observed Plasma Concentration (Cmax)
Time frame: Through 24 hours postdose
PK of ARO-DIMERPA: Time to Maximum Plasma Concentration (Tmax)
Time frame: Through 24 hours postdose
PK of ARO-DIMERPA: Area Under the Plasma Concentration (AUC) Versus Time Curve From Time Zero to 24 Hours (AUC0-24)
Time frame: Through 24 hours postdose
PK of ARO-DIMERPA: AUC Versus Time Curve From Time Zero to the Last Quantifiable Plasma Concentration (AUC0-t)
Time frame: Through 24 hours postdose
PK of ARO-DIMERPA: AUC Versus Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf)
Time frame: Through 24 hours postdose
PK of ARO-DIMERPA: Apparent Terminal Elimination Half-life (t1/2)
Time frame: Through 24 hours postdose
PK of ARO-DIMERPA: Apparent Systemic Clearance (CL/F)
Time frame: Through 24 hours postdose
PK of ARO-DIMERPA: Apparent Terminal-phase Volume of Distribution (Vz/F)
Time frame: Through 24 hours postdose
PK of ARODIMERPA: Recovery of Unchanged Drug (Ae) in Urine From Time Zero to 24 Hours Postdose
Time frame: Through 24 hours postdose
PK of ARO-DIMERPA: Percentage of Administered Drug Recovered (Fe) in Urine From Time Zero to 24 Hours Postdose
Time frame: Through 24 hours postdose
PK of ARO-DIMERPA: Renal Clearance (CLR)
Time frame: Through 24 hours postdose
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2025 (actual). Primary completion is estimated for Jul 2027, 19 months after the start.
Primary completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Jul 2027, on Oct 13, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hyperlipoproteinemia Type II →